Company ProfilePremium

Marinomed Biotech AG

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Marinomed Biotech AG - Company showcase

Year Founded & Workforce

2006

32 Employees

Marinomed Biotech AG logo

Marinomed Biotech AG Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Marinomed Biotech AG Overview

Marinomed Biotech AG was an Austrian science-driven biopharmaceutical company built on two proprietary platforms: Carragelose, an iota-carrageenan red-algae polymer with virus-blocking, allergen-blocking and moisturising properties, commercialised as an over-the-counter portfolio of nasal sprays, throat products and eye drops through roughly 20 licensing partners worldwide; and Marinosolv, a patented solubilisation technology that brings poorly water-soluble drugs such as budesonide and tacrolimus into aqueous solution, enabling lower doses, faster onset and preservative-free formulations for sensitive tissues like the nose and eye. After a first court-supervised restructuring in 2024, the company sold its revenue-generating Carragelose business to French CDMO Unither Pharmaceuticals for up to EUR 20 million, pivoting to an asset-light licensing model around Marinosolv (Budesolv, Tacrosolv, Satiasolv) and Solv4U services. Non-receipt of Unither earn-outs triggered a second insolvency in July 2026, culminating in court-ordered dissolution in September 2026.


Company's own description (Annual Financial Report 2025)

In its FY2025 annual report, Marinomed describes itself as a biopharmaceutical company focused on the invention, development and licensing of drugs, having achieved milestones in respiratory, infectious, immune and eye diseases based on patented platforms. Its stated model is to concentrate on what it does best — identifying substances and indications, early and mid-stage drug development, medical device development and partnering — while leveraging larger pharmaceutical partners for late-stage clinical development, regulatory management and marketing. Revenue may be generated through product sales, patents, data, licensing or similar transactions. Partners typically take over the entire commercial value chain from manufacturing to distribution in exchange for upfront, milestone and royalty payments, allowing Marinomed to remain "asset-light."

The latest standard corporate boilerplate (July 2026) described Marinomed as an Austrian, science-based biotech company with a growing development pipeline that develops patent-protected products on the Marinosolv platform, which improves solubility and bioavailability of hardly soluble compounds for autoreactive immune disorders.

Independent characterisation

Marinomed was, in substance, a micro-cap European platform biotech that for most of its listed life financed R&D from a modestly profitable-at-gross-level OTC medical-device franchise (Carragelose), supplemented by EIB venture debt, convertible notes and small equity raises. The Carragelose franchise benefited from a pandemic-era demand spike (FY2021–FY2022 revenue of EUR 11.6m and EUR 11.3m respectively) but normalised in FY2023 (EUR 9.2m) and collapsed in FY2024 (EUR 4.7m) as partner ordering faltered and the company entered insolvency. The Marinosolv platform produced clinically validated assets — Budesolv met all endpoints in a Phase III trial for allergic rhinitis, and Tacrosolv showed Phase IIa efficacy — but late-detected room-temperature stability problems derailed partnering for years. From March 2025 onward, Marinomed had essentially no recurring product revenue, relied on a EUR 5m upfront from Unither, small service fees and successive dilutive micro-raises, and carried a fixed restructuring-quota repayment schedule it could only meet if contingent earn-outs materialised. They did not, and the company failed.

Business model and revenue model mix

Revenue streamDescriptionStatus at dissolution
Product sales (Carragelose OTC)Supply of finished Carragelose nasal sprays, lozenges and eye drops to ~20 licensees/distributorsDivested to Unither (closed 28 Feb 2025); remaining stock sold to Unither
Licensing / milestones (Carragelose)Licence fees and milestones from regional partners (e.g., Procter & Gamble for US)Transferred to Unither with all contracts
Licensing / milestones (Marinosolv products)Upfront/milestone/royalty deals for Budesolv (Luoxin – Greater China; Swiss partner), Tacrosolv (none closed)Assets to be sold by administrator
Solv4U technology servicesFee-for-service feasibility and formulation studies; follow-on licences (Aché – Brazil, SPH Sine – China, Unither – France)Ceased with operations
Pharmaceutical servicesVirological, immunological, toxicological assays; ex-vivo models (fee-for-service)Ceased
Transition service agreementRegulatory, BD and R&D services to Unither post-closingCeased
Compounding (announced Apr 2026)Marinosolv-based solutions for compounding pharmacies; first revenues targeted Q4 2026/early 2027Never generated revenue
Disposal proceeds / earn-outEUR 5m fixed price received; up to EUR 15m earn-out contingent until mid-2027Earn-out disputed, not received

Quantified mix by stream is not publicly disclosed for FY2025 beyond the statement that EUR 5.0m of EUR 7.7m revenue was the Unither upfront and the remainder comprised delayed 2024 orders, inventory sale to Unither, other Carragelose-sale proceeds and Solv4U research revenue (Annual Financial Report 2025).

Value-chain position, customers and end markets

Marinomed sat in early-to-mid-stage drug and device R&D, outsourcing manufacturing (fill-finish via CMOs) and commercialisation. Customer types: (i) OTC pharmaceutical marketers and distributors (Carragelose era); (ii) mid-sized and large pharma licensees for Rx assets (Luoxin, Swiss partner, Phargentis); (iii) pharma/biotech formulation clients (Solv4U); (iv) planned compounding pharmacies. End markets: cough, cold and allergy consumer healthcare; allergic rhinitis Rx; ophthalmology (dry eye, inflammatory ocular surface disease, vernal keratoconjunctivitis); drug-delivery/bioavailability enhancement; respiratory inhalation (via Phargentis).

Strategy

Stated strategy (Annual Financial Report 2025, paraphrased themes)

Management characterised the 2024–2025 restructuring as an opportunity: it produced a EUR 18.9m restructuring gain, converted remaining unsecured liabilities into interest-free tranches, and — after scheduled repayments — would leave the company debt-free from mid-2027 except for real-estate financing and the two convertible bonds. The overarching goal was sustainable profitability, with an explicit aim of profitability from 2025 onward. The strategy shifted the revenue model from merchandise sales to licensing deals with upfront and milestone payments, complemented by earn-outs, the Unither service agreement and Solv4U services.

Four key projects (AR 2025)

#ProjectObjectiveOutcome by Oct 2026
aMaximise Carragelose earn-outSupport Unither integration (P&G US certification; eye-drop rollout) to unlock up to EUR 15m by mid-2027Failed: no earn-out received; Unither terminated negotiations; Marinomed alleged culpable delays and strategy change by Unither
bBudesolv licences and first approvalComplete MAA data; file first in Switzerland; sign further partnersSwiss term sheet only; MAA filing (targeted Q1 2026 per First Berlin) not confirmed
cFirst Tacrosolv partnershipLeverage reformulation and packaging; ride interest after Novaliq/Théa dealNo partnership announced
dExpand Solv4U and servicesGrow beyond feasibility studies; Satiasolv data; pharma servicesPhargentis inhalation term sheet (May 2026); compounding entry (Apr 2026); no material revenue before closure

Initiatives announced in the last 24 months

DateInitiativeTypeTargets / terms
Nov 2024Carragelose divestiture to UnitherPortfolio transformationUp to EUR 20m (EUR 5m fixed + up to EUR 15m earn-out)
Nov 2024Restructuring planFinancial restructuring30% quota (EUR 8.0m) to May 2027; up to 37% if earn-out exceeds plan
2,025Cost reductionCost programmeFTE down from 42 to 32; external research and patent costs cut
Jun 2025Budesolv Swiss partnershipLicensingExclusive Swiss (and Austrian per German release) rights; milestones + royalties
Sep 2025Capital increase + EUR 2.5m convertibleFinancingEUR 1.08m at EUR 17.50; CB conversion at EUR 15
Mar–Apr 2026Rights issueFinancingUp to 459,985 shares at EUR 14; EUR 2.23m net raised
Apr 2026Compounding servicesNew businessFirst revenue Q4 2026/early 2027
May 2026Phargentis inhalation licencePlatform licensingFee-for-service, milestones, royalties
Jul 2026Second restructuring and legal action vs UnitherRestructuring / litigation intentNew restructuring plan; legal remedies against Unither

Medium-term guidance

In March 2026, the CEO stated that the business plan projected profits for 2026 and subsequent years, driven by marketing of Budesolv and Tacrosolv. In a GBC AG interview (October 2025), management described a five-year vision of a profitable company with steadily rising Budesolv licence income. First Berlin (June 2025) modelled EBITDA of EUR 3.0m (2026E), EUR 3.3m (2027E) and EUR 3.3m (2028E), with equity turning positive in 2028E. All guidance has been superseded by the dissolution. ESG/sustainability commitments: no quantified targets disclosed.

Products & Services

Virology segment — Carragelose (divested Feb 2025)

Product lineDescriptionKey capabilitiesTarget customerStatus / yearPricing model
Carragelose virus-blocking nasal spraysIota-carrageenan nasal spray forming a protective gel layer on mucosaBroad-spectrum physical virus blocking; clinical data incl. SARS-CoV-2 inhibitionOTC consumers via pharma partnersMarketed since late 2000s; transferred to Unither 2025Supply price + licence fees (partner-specific, not disclosed)
Carragelose throat productsThroat sprays / lozengesSame mechanism for oropharynxOTC consumersTransferred 2025—
Carragelose allergy / allergen-blocking productsNasal products blocking allergensAllergen barrier; launched in Austria and MexicoAllergy sufferersLaunched 2023–2024 (per roic.ai summary); transferred 2025—
Carragelose eye dropsMoisturising dry-eye dropsLubrication/protectionDry-eye OTC marketLaunched in Austria by Sigmapharm H1 2025 (temporarily out of stock due to demand)—
US Carragelose (P&G)Nasal spray under Procter & Gamble for US marketUS certification in progressUS OTCAgreement 2022; US approval pending at FY2025 report—

Immunology segment — Marinosolv proprietary candidates

CandidateActive ingredientIndicationPhase (latest)Key data / specsPartnering
MAM-1004-1 / BudesolvBudesonide (solubilised)Severe allergic rhinitisFiling in preparation (Swiss MAA targeted)Met all Phase III endpoints; ~85% lower dose than comparable marketed products; reduction of nasal and asthmatic symptoms within three hours of first dose; no shaking; preservative-free; reformulated for stability with new patent protecting IP to 2043Luoxin (Greater China, 2021, USD 2m upfront); Swiss partner (2025, milestones + royalties)
MAM-1003-1 / TacrosolvTacrolimus (solubilised)Severe inflammatory ocular surface disease (model: allergic rhinoconjunctivitis; target incl. VKC)Phase IIPhase IIa: higher dose relieved eye and nose allergy symptoms after eight days; higher ocular tissue levels than Talymus suspension despite 95% lower concentration; reformulated with new primary packagingNo partner closed; interest reportedly increased after Novaliq–Théa CyclASol deal
MAM-1018-1 / SatiasolvCannabidiol (solubilised)Pain / immune reactionsPreclinicalOral preclinical model: significantly more efficient brain uptake vs oil-based comparatorMarketed via Solv4U
Phargentis inhalation formulationCombination of APIsRespiratory (inhalation)Formulation developmentTerm sheet 19 May 2026; worldwide exclusive Marinosolv licencePhargentis SA — fee-for-service, milestones, royalties
Tacrolimus eye drops for compoundingTacrolimusCompounding marketPre-launchProgress announced 2026 (MarketScreener headline)Planned compounding channel

Others segment — Solv4U and services

OfferingDescriptionLaunchRevenue modelNamed clients
Solv4U feasibility studiesDemonstrate Marinosolv solubilisation of client APIsNov 2021Fee-for-serviceMultiple (not all disclosed)
Solv4U formulation optimisation & licensingFollow-on development and licence2023 onwardMilestones + licence feesAché (Brazil), SPH Sine (China), Unither (France)
Pharmaceutical assaysVirological, immunological, toxicological assays2,024Fee-for-service—
Ex-vivo modelsTissue models for external customers2,025Fee-for-service—
Compounding solutionsMarinosolv-enabled formulations for compounding pharmaciesAnnounced 22 Apr 2026; revenue expected Q4 2026/early 2027Product/solution supplyNone (ceased before launch)

Platform technology — Marinosolv specification summary

Per the FY2025 annual report, Marinosolv is a set of excipients that solubilises small hydrophobic molecules and peptides for liquid and semi-solid dosage forms. Claimed advantages: clinical validation; broad applicability; tolerability on eyes and nose; faster onset than suspensions; significantly lower dose with potential side-effect reduction; higher target-tissue bioavailability; possibility of sterile filtration and preservative-free formulations; reduced environmental API burden; scalable process.

Financial Narrative

Basis: FY2021–FY2023 figures from company press releases and aggregators (consolidated/UGB as reported at the time); FY2024–FY2025 from the Annual Financial Report 2025 (UGB single entity). "n/d" = not publicly disclosed or not verifiable from retrieved sources. Derived figures are labelled.

Income statement

Notes: EBITDA FY2021–FY2024 derived from reported EBITDA margins (boersengefluester.de: -30.44%, -37.59%, -48.48%, -137.68%) applied to revenue; First Berlin (June 2025) shows FY2023 EBITDA of EUR -4.52m to -4.54m and FY2024 of EUR -6.54m to -6.55m, consistent. FY2025 EBITDA derived as operating result EUR 18.67m plus D&A EUR 0.31m. FY2025 EPS from Investing.com (basic) and Yahoo Finance (diluted) — aggregator figures. FY2021–FY2022 EPS from FY2022 results release. FY2022 revenue derived from company statement that revenue rose 16.5% excluding the EUR 1.9m 2021 milestone (EUR 9.7m × 1.165 ≈ EUR 11.3m), consistent with net-margin data.

Margins

Revenue CAGR FY2021–FY2025: (7.7 / 11.6)^(1/4) − 1 = −9.7% p.a. FY2025 margins are meaningless as operating indicators: they are driven by the EUR 18.9m non-cash restructuring gain and the EUR 5.0m one-off disposal upfront recognised in revenue.

Commentary. The income statement tells a three-act story. Act one (FY2021–FY2022) shows a pandemic-boosted Carragelose franchise at EUR 11–12m revenue with persistent EUR 6m net losses funded by the IPO and EIB loan, as R&D (approximately EUR 7.5m in FY2021 per company release) outstripped gross profit. Act two (FY2023–FY2024) is the unwind: post-pandemic normalisation cut revenue 19% in FY2023; in FY2024 partner orders and revenue expectations failed, and the company entered insolvency with a EUR 15.4m net loss inflated by EUR 6.7m of extraordinary expenses from termination of the EIB agreements (EIB claim rose from the EUR 15m principal to EUR 24.1m on early termination) and a EUR 0.65m impairment on the office building. Act three (FY2025) is an accounting profit of EUR 18.0m that masks an underlying operating loss: stripping out the EUR 18.9m restructuring gain and the EUR 5.0m Unither upfront, adjusted operating result was roughly EUR −5.2m, comparable to prior years on a far smaller revenue base. Personnel costs fell 17% (42 to 32 FTE) and purchased services fell from EUR 1.1m to EUR 0.2m, but other operating expenses stayed flat at EUR 2.75m because of the cyber-fraud loss and deal advisory costs.

Balance sheet

Sources: AR 2025 balance sheet (FY2024–FY2025); cash FY2021 per Q1 2022 PR (EUR 5.8m at 31 Dec 2021); cash FY2022 and FY2023 and equity FY2023 per First Berlin (June 2025) model (EUR 8.12m opening 2023 cash; EUR 2.56m closing 2023; equity EUR −11.5m); FY2022 equity EUR −4.15m per boerse-express aggregator (year mapping uncertain, flagged). Note discrepancy: First Berlin shows FY2024 equity of EUR −25.0m versus EUR −26.2m in the audited UGB single-entity statement; the audited figure is used.

FY2025 liability detail (AR 2025): bank liabilities EUR 8.37m (EUR 2.78m due within one year; EUR 5.59m beyond), convertible bonds EUR 3.04m (EUR 2.56m within one year), trade payables EUR 0.16m, other liabilities EUR 0.58m, accruals EUR 0.63m. Bank liabilities include restructuring-quota obligations to the EIB and real-estate loans of approximately EUR 4.0m secured on the Korneuburg HQ (ERP loan rate raised to 8.5% after insolvency). By July 2026, total liabilities had risen to approximately EUR 27.9m, including 2024 claims that became enforceable again once the restructuring plan could not be fulfilled (EQS, 22 July 2026).

Commentary. Marinomed carried negative equity from at least FY2022, legally tolerated under Austrian insolvency law only because management maintained a positive going-concern forecast. The 2025 restructuring compressed debt from EUR 28.2m to EUR 11.4m, but cash of EUR 1.0m against EUR 6.1m of liabilities due within twelve months (current ratio ≈0.24) left the company entirely dependent on contingent inflows. The auditor's "material uncertainty related to going concern" framing in the FY2025 notes explicitly assumed substantial but unsecured payments in Q2 and Q3 2026 — payments that did not arrive.

Cash flow

Sources: AR 2025 (FY2024–FY2025); First Berlin June 2025 (FY2023). Note: H1 2025 operating cash flow was EUR −0.2m and Q1 2025 was positive EUR +2.9m owing to the Unither upfront; the FY2025 annual operating cash flow of EUR −1.1m implies the EUR 5m was largely consumed by quota payments (classified as operating/financing outflows) and running costs. First Berlin had forecast positive operating cash flow of EUR 3.0m for 2025E; actual was negative.

Ratios

ROE and debt/equity are not meaningful given negative equity in every year with data. FY2025 ROA, net debt/EBITDA and interest coverage are distorted by the restructuring gain and should not be interpreted as indicators of operating health. Cash conversion cycle is not computable after inventory fell to near zero in FY2025 (EUR 1.1k).

Interim data points (2025–2026)

Sources: Q1 2025 and H1 2025 results releases. H1 2026 report (scheduled 16 Sep 2026) was postponed indefinitely and never published.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsProducts / servicesStatus

Virology

Carragelose platform

Carragelose nasal sprays (virus-blocking, allergy, moisturising), throat sprays/lozenges, eye drops; licences to ~20 partners

Divested to Unither, closed 28 Feb 2025

Immunology

Proprietary Marinosolv drug candidates

Budesolv (MAM-1004-1), Tacrosolv (MAM-1003-1); Satiasolv (MAM-1018-1) referenced under Solv4U marketing

Assets in insolvency estate

Others

Solv4U unit

Formulation feasibility/optimisation studies, licences, pharmaceutical assays, ex-vivo models

Ceased

Segment revenue (EUR Mn)

Segment revenue (EUR Mn)FY2021FY2022FY2023FY2024FY2025

Virology (Carragelose) revenue

9.711.2———

Immunology (Marinosolv milestones) revenue

1.90.0———

Unither upfront (recognised as revenue)

0.00.00.00.05.0

Total revenue

11.611.39.24.77.7

Group Entities

EntityRelationshipStatus

Marinomed Biotech AG

Parent / sole operating entity

Dissolved Sep 2026; in liquidation

Marino Immo GmbH

Former 100% property subsidiary

Sold by notarial deed 19 Dec 2024; disposal effective Jan 2025

Branches

None (per AR 2025)

—

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (EUR Mn)

11.611.39.24.77.7

Revenue YoY growth (%)

—-2.6-18.6-48.462.0

Other operating income (EUR Mn)

———0.119.5

Cost of materials and purchased services (EUR Mn)

———3.81.4

Gross profit, revenue less materials/services (EUR Mn, derived)

———1.06.3

Personnel expenses (EUR Mn)

———4.84.0

Other operating expenses (EUR Mn)

———2.82.8

EBITDA (EUR Mn, derived)

-3.5-4.3-4.5-6.519.0

Depreciation and amortisation (EUR Mn)

———1.10.3

Operating result / EBIT (EUR Mn)

———-7.618.7

Financial result (EUR Mn)

———-7.9-0.5

Pre-tax income (EUR Mn)

———-15.518.1

Net income (EUR Mn)

-5.9-6.4-6.8-15.418.0

EPS basic (EUR)

-4.0-4.3——9.79

EPS diluted (EUR)

————9.76

Dividend per share (EUR)

00000

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Gross margin, revenue less materials/services (%)

———20.381.7

EBITDA margin (%)

-30.4-37.6-48.5-137.7246.8

Operating (EBIT) margin (%)

———-160.1242.7

Net margin (%)

-50.7-56.7-74.1-324.6234.3

Balance Sheet

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (EUR Mn)

———8.26.0

Cash and equivalents (EUR Mn)

5.88.12.61.71.0

Intangible assets (EUR Mn)

———0.090.01

Goodwill (EUR Mn)

00000

Land and buildings (EUR Mn)

———4.44.2

Short-term financial debt incl. convertibles (EUR Mn)

———28.25.3

Long-term financial debt incl. convertibles (EUR Mn)

———0.06.1

Total financial debt (EUR Mn)

———28.211.4

Net debt (EUR Mn)

———26.510.5

Shareholders' equity (EUR Mn)

—-4.2-11.5-26.2-7.0

Working capital, current assets less current liabilities and accruals (EUR Mn, derived)

———-30.9-5.3

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (EUR Mn)

——-3.7-2.4-1.1

Capex / investing cash flow (EUR Mn)

———-0.10.0

Free cash flow (EUR Mn, derived)

———-2.5-1.1

Financing cash flow (EUR Mn)

——-1.71.60.3

Net change in cash (EUR Mn)

——-5.6-0.9-0.8

Dividends paid (EUR Mn)

00000

Share buybacks (EUR Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROA, net income / average total assets (%)

—255

Current ratio (x)

0.100.24

Net debt / EBITDA (x)

—0.55

Interest coverage, EBIT / interest expense (x)

-0.9634.4

Asset turnover, revenue / average assets (x)

—1.09

Income Statement

MetricQ1 2024Q1 2025H1 2024H1 2025

Revenue (EUR Mn)

0.746.532.427.18

Operating result / EBIT (EUR Mn)

-1.8622.22-3.1820.97

Net result (EUR Mn)

-2.1822.12——

R&D expenses (EUR Mn)

——2.391.40

Cash at period end (EUR Mn)

1.714.570.91.5

Region revenue (EUR Mn)

Region revenue (EUR Mn)FY2023FY2024FY2025

Total revenue

9.24.77.7

Valuation Snapshot

MetricValueBasis

Last price

EUR 4.00 (17 Oct 2026)

Investing.com

IPO price

EUR 75.00 (1 Feb 2019)

AR 2025

Return since IPO

−94.7%

Derived

1-year change

approx. −80%

Investing.com

YTD 2026 change

approx. −77% (as of 28 Aug 2026 at EUR 4.40)

MarketScreener

52-week high / low

EUR 21.00 / EUR 2.20

comdirect / Investing.com

3-year and 5-year returns

Not reliably retrievable; 5-year return deeply negative (IPO-era prices ~EUR 75)

—

Trading regime

Auction trading on Vienna Stock Exchange since Aug 2026 (market maker RBI withdrew 22 Jul 2026)

börse-global; EQS

Average volume (3m)

approx. 1,450 shares/day

Investing.com

Share Price

MetricIPO Feb 2019Q2 2025 peakSep 2025 placementMar 2026 rights issueAug 2026Oct 2026

Price or issue price (EUR)

75.0020.0017.5014.005.404.00

Share Price & Returns

DateInstrumentShares / nominalPrice (EUR)Gross proceeds (EUR Mn)

Sep 2024

Cash capital increase (no subscription rights)

154,0535.000.77

Dec 2024

Private placement

83,7508.000.67

Jan 2025

EIB convertible

84,768 conversion shares

5.00 conv.

0.42 nominal

Sep 2025

Cash capital increase (nine investors)

61,60717.501.08

Q4 2025

Convertible bond

166,666 conversion shares

15.00 conv.

2.50

Apr 2026

Rights issue

159,039 (of up to 459,985)

14.00

2.23 net

Valuation Multiples

MultipleMarinomedComment

Market cap

EUR 8.0m

1,998,979 shares

Enterprise value (approx.)

EUR 18.4m

Market cap + FY2025 financial debt EUR 11.4m − cash EUR 0.95m; July 2026 liabilities of EUR 27.9m imply higher EV

P/E (TTM)

~0.4x

Meaningless: restructuring gain

EV/EBITDA (FY2025)

~1.0x

Meaningless: restructuring gain

EV/Sales (FY2025)

~2.4x

One-off revenue

P/B

n/m

Negative equity

Analyst Ratings & Targets

BrokerLast actionDateRating / target

First Berlin Equity Research (Alexander Rihane)

Rating and target moved to Under Review

20 Jul 2026

Under Review (previously Buy; initiated 30 Jun 2025)

GBC AG

Buy

1 Oct 2025

Buy; target horizon 31 Dec 2026 (target value n/d)

MarketScreener consensus

P/E 2026E 3.55x; 2027E 3.01x (stale, pre-insolvency)

Aug 2026

—

Margin Analysis (%) (Nov 2025–Beyond 2027)

ObligationNov 2025May 2026Nov 2026May 2027Beyond 2027

EIB quota payments (% of claim)

555100

Other creditors quota payments (% of claim)

551000

Analyst Conclusions

Management guidance

The last management guidance (March–May 2026) projected profits for 2026 and later years from Budesolv and Tacrosolv marketing, first compounding revenue in Q4 2026/early 2027, and debt-freedom (ex-property and convertibles) from mid-2027. All guidance is void following the court-ordered dissolution on 24 September 2026. No consensus growth expectations remain valid.

Bull-case arguments (residual — relevant to asset value and creditor recovery, not equity)

  1. Unither claim may have value: Up to EUR 15m in contractual earn-outs remains disputed; if the administrator litigates successfully, recoveries could materially exceed the estate's other assets.

  2. Marinosolv assets are clinically de-risked: A Phase III-positive Budesolv with IP to 2043 and a Phase II Tacrosolv could attract a buyer in an administrator-led sale, especially given demonstrated partner interest (Luoxin, Swiss partner, Phargentis).

  3. Tangible real estate: Korneuburg land and buildings carried at EUR 4.2m provide hard-asset recovery for secured lenders.

Bear-case arguments

  1. Equity likely worthless: Liabilities of ~EUR 27.9m versus total assets of ~EUR 6.0m at end-2025 imply shareholders rank behind a large creditor shortfall.

  2. Distressed-sale discount: Assets with unresolved stability/regulatory histories and no team (operations ceased) typically sell at deep discounts in liquidation.

  3. Litigation uncertainty and cost: The Unither earn-out depends on proving culpable delay; an insolvency estate may lack resources to pursue protracted cross-border litigation.

Catalysts and monitorables (next 12 months)

MonitorableWhy it matters
Administrator's asset-sale process (Marinosolv IP, Budesolv, Tacrosolv, Satiasolv, real estate)Determines creditor recovery
Any legal action or settlement with UnitherLargest potential recovery source
Insolvency quota announcementsRecovery for EIB and unsecured creditors
Delisting decision by Vienna Stock Exchange / FMAEnd of equity trading
Fate of Luoxin, Swiss and Phargentis contractsTransferability to acquirer
Treatment of convertible bonds and EIB claimsRanking in liquidation
Publication (if any) of H1 2026 financials or administrator reportsTransparency on estate value

Analyst verdict

Marinomed Biotech AG is a cautionary case study in how a scientifically credible platform company can fail on balance-sheet architecture rather than science. The Marinosolv technology generated genuinely differentiated clinical data — a Phase III win for Budesolv at a fraction of the incumbent dose, and encouraging Phase IIa results for Tacrosolv — yet the company never assembled the capital or the partner leverage to convert that data into approvals. Two compounding errors proved fatal. First, room-temperature stability problems surfaced only after pivotal development, resetting regulatory and partnering timelines by years. Second, the 2024 restructuring was engineered around contingent consideration: the creditor plan's 30% quota relied on up to EUR 15m of Unither earn-outs that Marinomed did not control, while the only certain consideration, EUR 5m, was quickly absorbed by quota payments, running costs and a EUR 677k cyber-fraud loss. The FY2025 accounting profit of EUR 18.0m was almost entirely a non-cash restructuring gain; adjusted for that and the one-off Unither upfront, the business was still burning roughly EUR 5m a year with under EUR 1m of cash. Successive micro-raises at falling prices (EUR 17.50 in September 2025, EUR 14 in March 2026 with only about a third of the offer taken up) signalled exhausted investor support well before the July 2026 filing. With the company dissolved by the Korneuburg insolvency court on 24 September 2026 and operations ceased, the listed equity should be regarded as having negligible expected value; any residual worth accrues first to secured lenders (Korneuburg property), the EIB and unsecured creditors. The only meaningful upside variable is the administrator's pursuit of the Unither earn-out claim and the price achievable for the Marinosolv IP estate. For investors, the verdict is unequivocal: avoid the equity; for strategic buyers, the Budesolv and Tacrosolv assets may represent an inexpensive option on validated solubilisation technology.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenureBackgroundCompensation (latest)

Dipl.-Ing. Dr. Andreas Grassauer

CEO, co-founder

Founder 2006; management board representative since 2 Jun 2017

Co-founder from the University of Veterinary Medicine Vienna spin-off; long-time CEO through IPO, two insolvencies

Not publicly disclosed in retrieved sources

Mag. Dr. Eva Prieschl-Grassauer

CSO, co-founder

Founder 2006; representative since 2 Jun 2017

Scientific lead on Carragelose and Marinosolv

Not publicly disclosed in retrieved sources

Pascal Schmidt

CFO (former)

Until 31 Jan 2025

Led finance through IPO-era capital markets activity and 2024 restructuring

—

“—” = not publicly disclosed.

Board of Directors

NameRoleNotes

Dr. Simon Nebel, MBA

Chairman

Registered 2 Jun 2017; chair through 2025

Mag. Brigitte Ederer

Member

Listed in register extracts

Dr. Elisabeth Lackner

Member

Elected at June 2022 AGM

Dr. Karl Mahler

Member

Listed in register extracts

Dr. Eva Hofstädter-Thalmann

Member (from 2023)

Elected 2023; global pharma expert

Ulrich Kinzel

Member (from 2022)

Elected June 2022

Board & Management Changes

DateChangeContext

31 Jan 2025

CFO Pascal Schmidt departs

Immediately after end of first restructuring

Feb 2025

Supervisory board composition changes (register filings)

Post-restructuring governance reset

Late Jul 2026

Administrator Dr. Ulla Reisch appointed; management loses control (proceedings without self-administration)

Second insolvency

24 Sep 2026

Company dissolved; administrator assumes liquidation

Wind-up motion granted

Major Shareholders

HolderStake (%)Type

Andreas Grassauer (CEO)

6.6

Founder / insider

Eva Prieschl-Grassauer (CSO)

6.6

Founder / insider

Hermann Unger

6.2

Co-founder

Abdulmohsen Al Sheikh

3.5

Former Acropora investor (stake split from Acropora)

Mohammed Al Sheikh

3.5

Former Acropora investor

Free float

73.7

Retail / institutional

Competitive Landscape

Competitors by Segment

SegmentCompetitorRelevanceComparative scale

Solubilisation / ophthalmic formulation

Novaliq GmbH (EyeSol; CyclASol, partnered with Théa)

Direct: water-free/solubilised ocular formulations; Marinomed's AR named it as benchmark for Tacrosolv

Private; revenue n/d

Ophthalmic cyclosporine

Harrow (VEVYE, cyclosporine eye drops approved by FDA May 2023)

Competes with Tacrosolv in dry eye / ocular inflammation

—

Ophthalmic immunomodulators

Sun Pharma (Cequa), Santen, Bausch + Lomb

Established dry-eye and ocular inflammation franchises

—

Allergic rhinitis Rx/OTC corticosteroids

GSK/Haleon (fluticasone), Sanofi/Opella (triamcinolone OTC), Viatris (azelastine/fluticasone combo), Glenmark (olopatadine/mometasone)

Incumbent suspensions Budesolv aimed to displace

—

Budesonide nasal

AstraZeneca/OTC licensees (budesonide nasal sprays)

Same molecule in suspension

—

Bioavailability-enhancement CDMOs

Lonza, Catalent, Ascendia, Particle Sciences-type specialists

Compete with Solv4U for formulation services

—

Compounding

Fagron and national compounding suppliers

Compete with planned compounding business

—

Carragelose (legacy, now Unither)

Iota-carrageenan and barrier sprays from other OTC players

Competition now borne by Unither

Unither: EUR 475m sales (2023)

Peer Comparison FY2025

MetricMarinomed (FY2025)Unither PharmaceuticalsNovaliqHarrow

Revenue

EUR 7.7m

EUR 475m (2023)

n/d (private)

n/d in this research

Revenue growth

+62% (one-off driven)

———

Operating margin

n/m (restructuring gain)

———

R&D intensity

34% of revenue

———

Ownership

Listed, dissolved

Private

Private

Listed (Nasdaq)

Company Snapshot

$8.7M

Revenue

32

Employees

2006

Founded

SWOT Analysis

Strengths

  • Clinically validated platform: Budesolv met all endpoints in a Phase III allergic-rhinitis trial (AR 2025).
  • Dose differentiation: Budesolv achieves efficacy with ~85% less active ingredient than comparable marketed products; Tacrosolv reached ocular tissue levels with a 95% lower concentration than Talymus (AR 2025).
  • Long IP runway: New Budesolv formulation patent protects product IP to 2043 (AR 2025).
  • Partner validation: Luoxin licence with USD 2m upfront and double-digit USD million milestones (2021); Phargentis worldwide licence term sheet (May 2026).
  • Monetised legacy asset: Carragelose sold for EUR 5m fixed plus up to EUR 15m (closed Feb 2025).
  • Lean cost base: Personnel cost reduced from EUR 4.8m to EUR 4.0m and purchased services from EUR 1.1m to EUR 0.2m in FY2025.

Weaknesses

  • Negative equity: EUR −7.0m at end-2025 even after an EUR 18.9m restructuring gain (AR 2025).
  • Liquidity: Cash EUR 0.95m vs EUR 6.07m liabilities due within one year at 31 Dec 2025.
  • No recurring revenue: FY2025 revenue of EUR 7.7m included a one-off EUR 5.0m upfront; underlying revenue ~EUR 2.7m.
  • Stability failures: Late-detected room-temperature stability issues for Budesolv and Tacrosolv delayed partnering and forced regulatory re-strategy (AR 2025).
  • Persistent losses: Net loss in every year since foundation except FY2025 (accounting gain); EUR 52.9m accumulated deficit.
  • Control weaknesses: EUR 677k lost to cyber fraud in March 2025.

Opportunities

  • Bioavailability enhancement market of USD 3.8bn growing ~5.6% p.a. (AR 2025).
  • Allergy pharma market projected to reach USD 33.6bn by 2030.
  • Swiss reference-country route for simplified Budesolv approvals in other markets.
  • Ophthalmology partnering momentum after Novaliq's CyclASol partnership with Théa.
  • Compounding channel offering nearer-term revenue than Rx registration (announced April 2026).
  • Legal claim against Unither for up to EUR 15m earn-out, which the administrator may pursue.

Threats

  • Counterparty risk realised: Unither paid no earn-out and terminated negotiations (July 2026).
  • Insolvency/dissolution: Company dissolved 24 Sep 2026; shareholder recovery likely nil.
  • Regulatory heterogeneity: Differing classifications across countries delayed Budesolv (AR 2025).
  • US regulatory delays: FDA staffing cuts flagged as risk to P&G Carragelose approval (AR 2025).
  • Competitive ophthalmic entrants: VEVYE approved by FDA (May 2023), under review in Europe and China.
  • Capital-market exclusion: Market maker withdrew (July 2026); auction-only trading.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
2 Apr 2025Disclosure of cyber-fraud: approx. EUR 677k transferred to third parties outside the EEAMaterial cash loss (~13% of the Unither upfront); investigation ongoing
Apr 2025FY2024 annual report publishedAudited FY2024 loss EUR 15.4m; negative equity EUR −26.2m
Apr 2025First EIB quota payment (5%) dueRestructuring plan execution
May 2025Q1 2025 results: revenue EUR 6.5m, EBIT EUR 22.2m incl. EUR 18.9m restructuring gain; cash EUR 4.6mAccounting turnaround; share rallied above EUR 20
May 2025Second quota payment to other creditors (5%)Plan execution
6 Jun 2025Binding term sheet for Budesolv with Swiss partnerFirst European Budesolv deal
Jun 2025AGM (11 June 2025)Routine governance
30 Jun 2025First Berlin initiates coverage with BuyExternal validation of turnaround thesis
H1 2025Carragelose eye drops launched in Austria by Sigmapharm; temporary stock-out from demandEarn-out relevant
Jul 2025Impaired loan fully repaid; impairment reversedMinor positive
1 Sep 2025Key terms agreed for secured EUR 2.5m convertible bondLiquidity bridge
16 Sep 2025Capital increase: 61,607 shares at EUR 17.50 (EUR 1.08m)Dilutive financing
17 Sep 2025H1 2025 results: revenue EUR 7.2m, EBIT EUR 21.0m; cash EUR 1.5m; CEO says no further capital measures plannedGuidance later contradicted
23 Sep 2025EGM approves Conditional Capital 2025 for EUR 2.5m CB (conversion EUR 15)Financing
1 Oct 2025First Berlin (Buy) and GBC (Buy) research updatesSell-side optimism on Budesolv licensing
Nov 2025Quota payments due (EIB 5%, others 5%)Plan execution; strain on cash
19 Mar 2026Preliminary FY2025 results; rights issue of up to 459,985 shares at EUR 14 to cover ~EUR 2m need; earn-out delays disclosedEarly warning signal
16 Apr 2026Rights issue registered: 159,039 shares (~35% take-up of maximum)Weak investor support
21–22 Apr 2026FY2025 Annual Financial Report published with going-concern material-uncertainty languageDisclosure of fragility
22 Apr 2026Entry into compounding services announcedNew revenue attempt
May 2026Quota payments due (EIB 5%, others 5%); management interview with GBC (11 May 2026)Cash outflows
19 May 2026Phargentis SA term sheet for worldwide Marinosolv inhalation licencePlatform validation, small near-term fees
16–17 Jul 2026Ad hoc: plan to apply for restructuring without self-administration after Unither negotiations failInsolvency
20 Jul 2026First Berlin moves rating and target to "Under Review"Coverage effectively suspended
22 Jul 2026Filing at Regional Court Korneuburg; liabilities ~EUR 27.9m; ~30 staff; RBI market making terminated; H1 2026 report postponedSecond insolvency formalised
Late Jul 2026Proceedings opened; Dr. Ulla Reisch appointed administratorManagement loses control
Aug 2026Vienna Stock Exchange moves share from continuous to auction tradingLiquidity collapse
24 Sep 2026Administrator moves to wind up; company dissolved; investor talks unsuccessful; licensing-rights sale not completed in timeTerminal event
29 Sep 2026Ad hoc on cessation of operations and closureFormal market disclosure
Oct 2026Administrator to begin sale of company assetsCreditor recovery phase

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue fell from EUR 11.6 Mn in FY2021 to EUR 7.7 Mn in FY2025.
Marinomed Biotech AG — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2021FY2022FY2023FY2024FY2025
Revenue11.611.39.24.77.7
Cost of materials and purchased services———3.81.4
Gross profit, revenue less materials/services———16.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.